A Multiple Ascending Dose Study of LW402 in Healthy Volunteers

Phase 1 Completed 36 enrolled Shanghai Longwood Biopharmaceuticals Co., Ltd.

RandomizedSequentialQuadruple-blindTreatment

Summary

This Phase 1, double-blind (sponsor open), placebo controlled study will assess the safety, tolerability and pharmacokinetics of multiple doses of LW402 tablets in healthy volunteers.

Timeline

Start: 2025-10-15
Primary completion: 2025-12-09
Completion: 2025-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LW402	Unknown	200 mg	Oral
Subject	LW402	Unknown	250 mg	Oral
Subject	LW402	Unknown	300 mg	Oral

Indications

No indication recorded.